91精品乱码久久蜜桃麻豆,www.17c.com国产大片,寡妇高潮一级毛片免费看,久久人妻少妇嫩草av
c4d1d2-pcbanner-356.jpg c4d1d2-phbanner-772.jpg
Products
RBD1016

Being developed as the first GalNAc-siRNA drug based on Ribo's proprietary liver-targeting delivery technology RIBO-GalSTARTM for the treatment of Hepatitis B, RBD1016 covers patient population with hepatitis B virus genotypes A-E and I, which represent the vast majority of hepatitis B patients in Europe, the United States and Asia. RBD1016 has demonstrated well tolerated safety profile and pharmacokinetic characteristics expected for GalNAc-siRNA in clinical studies. Pharmacodynamic data on hepatitis B patients indicate that RBD1016 exhibits a relatively consistent and long-lasting inhibitory effect on HBsAg, HBV DNA, HBV RNA, and HBcrAg.

 

A Phase 1a study in Australia and as Phase 1b study in Hong Kong have been completed. A global multicenter Phase 2 clinical study targeting Hepatitis B is in progress.  A clinical trial application for a phase 2a study in Hepatitis D patients has been approved by EMA, and the study is ongoing.

RBD5044

RBD5044, a GalNAc-siRNA drug based on Ribo's proprietary liver-targeting delivery technology RIBO-GalSTARTM, is being developed for treatment of triglycerides (TGs)-type hypertriglyceridemia. RBD5044 inhibits the expression of ApoC3 (Apolipoprotein C-III) to reduce the TGs level in blood by increasing the uptake of lipoprotein lipase and hepatocyte receptor-mediated residual particle and elevating the hydrolysis of triglycerides (TGs) on triglyceride-rich lipoproteins (TRLs). Currently, RBD5044 is undergoing a phase I clinical trial in Australia, and the preliminary results showed good safety profile. A clinical trial application for Phase 2a study in Europe is under preparation.

RBD4059

RBD4059, a GalNAc-siRNA drug based on Ribo's proprietary liver-targeting delivery technology RIBO-GalSTARTM, is being developed for treatment of thrombotic diseases. RBD4059 inhibits the expression of FXI in hepatocytes to reduce the activation of endogenous coagulation pathways, thus resulting in anticoagulant/antithrombotic effects. As the First-In-Class siRNA drug targeting FXI, RBD4059 is undergoing a phase 1 clinical trial in Australia, and the preliminary results showed good safety profile, long-acting and strong inhibitory effectiveness. A clinical trial application for Phase 2a study has been approved by EMA, and the study is ongoing.

RBD7022

RBD7022, a GalNAc-siRNA drug based on Ribo's proprietary liver-targeting delivery technology RIBO-GalSTARTM, is being developed for the treatment of hyperlipidemia. RBD7022 inhibits the expression of PCSK9 (proprotein convertase subtilisin/kexin type 9), to lower to reduce LDL-R (low-density lipoprotein receptor) lysosomal degradation and to increase the number of LDL-R on the surface of liver cells, thus reducing LDL-C levels in the blood. Currently, a phase 1 clinical trial for RBD7022 is being conducted in China. The rights for development, manufacture and commercialization of RBD7022 in Mainland China, HK, and Macau has been licensed out to Qilu Pharmaceutical.

RBD1007

Designed as a siRNA, RBD1007 inhibits the expression of the Caspases 2 gene via RNAi mechanism by stopping retinal ganglion cell (RGC) apoptosis and secondary axonal degeneration, thereby preventing further deterioration of vision and visual field in the diseases and achieving therapeutic effect of vision protection. RBD1007 holds the potential of becoming the First-In-Class neuroprotective agent being developed to treat non-arteritic anterior ischemic optic neuropathy (NAION), for which there is no standard therapy at present. One Phase 1 clinical study and one Phase 2/3 international multi-center clinical study (including 34 Chinese subjects) have been completed. The clinical data analysis supports further development of the drug for treatment of NAION targeting a specific subpopulation with greatest unmet medical need.

RBD7007

RBD7007, a GalNAc-siRNA drug based on Ribo's proprietary liver-targeting delivery technology RIBO-GalSTARTM, is being developed for treatment of Complement-related diseases. RBD7007 inhibits the expression of complement components in hepatocytes to reduce the overactivation of the complement system, achieving the effect of treating complement-related diseases. RBD7007 has demonstrated robust and long-duration pharmacological effects in cynomolgus monkeys, holding the potential to be Best-In-Class. A clinical trial application for a first-in-human study has been approved by EMA, and the study is ongoing.

RBD8088

RBD8088,the first anti-tumor oligonucleotide drug conjugate developed based on Ribo's proprietary tumor-targeting delivery technology RIBO-OncoSTARTM, is able to penetrate the blood-brain barrier and specifically target glioma cells, thereby exerting therapeutic effects. As the First-In-Class oligonucleotide therapeutic globally, RBD8088 is currently in the preclinical development stage, aiming to initiate a first-in-human clinical trial in 2025. RBD8088 holds the potential to be a novel, safe and efficacious therapeutic drug for glioma treatment.

91精品国产人妻女教师 | 精品三级AV在线观看入口 | 激情放荡性小说在线视频xx | 91av网站视频观看 | 农村乱子伦一区二区三区 | 国产精品久久久午夜夜伦鲁鲁 | 亚洲精品中文字幕无码久久久久久 | 久久精品秘 一区二区国产 亚洲精品成人A片动漫 | 丰满少妇毛多大隂户视频 | 小黄书网页版入口免费观看 | 亚洲AV日韩AV不卡在线观看 | 国产做受 高潮久久 | 97人人妻人人添人人澡 | 一级视频在线观看 | www国产国产九九99 | 高清无码一区二区三区四区 | 免费AV一区二区三区 | www.99热在线观看 | 国产三级三级三级看三级 | 波多野结衣一区二区香蕉加勒比 | 性生片AAAA免费看 | 成人在线免费观看91 | 国产成人三级精品夜夜骚 | 欧美黑人又大又粗的特点 | 国产三级片视频在线观看 | 色费女人毛片A级视频 | 中国老妇女爽到高潮 | 成人A片产无码免费视频奶头软件 | 亚洲国产精品一区二区久久阿宾 | 日韩理论电影中文字幕 | 91丨人妻丨大屁股 | 影音先锋在线资源网站 | 波多野结衣 一区 二区 | 无码人妻一区二区三区神彩美 | 高清无码免费在线观看成人 | 国产精品久久久久的角色 | 国产无遮挡无黄又爽农村妇女 | 国产高清视频在线 | 在线观看国产黄色视频 | 一区二区三区四区少富 | 中日韩午夜理伦电影免费 |